Posted by Michael Wonder on 26 Sep 2019
ICER releases draft evidence report on rheumatoid arthritis therapies
26 September 2019 - Public comment period now open until 24 October 2019; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for rheumatoid arthritis.
This draft report will be open to public comment until 5pm ET on 24 October 2019. Based on stakeholder feedback, ICER may revise key assumptions and findings for its Evidence Report, which will be published on 7 November 2019. The Evidence Report will be subject to deliberation during a public meeting of the California Technology Assessment Forum, one of ICER’s three independent evidence appraisal committees, on 7 November 2019.
